



Clinical trial results:

Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2019-004430-42 |
| Trial protocol | DE AT |
| Global end of trial date | 04 January 2023 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 06 March 2024 |
| First version publication date | 06 March 2024 |

Trial information

Trial identification

| | |
|-----------------------|---------|
| Sponsor protocol code | AHA-EMI |
|-----------------------|---------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04188639 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GWT-TUD GmbH |
| Sponsor organisation address | Freiberger Str. 33, Dresden, Germany, 01067 |
| Public contact | Medical Consulting, GWT-TUD GmbH, +49 35125933100, medical.consulting@g-wt.de |
| Scientific contact | Medical Consulting, GWT-TUD GmbH, +49 35125933172, medical.consulting@g-wt.de |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 14 November 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 04 January 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 04 January 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the present study is to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

Protection of trial subjects:

An independent data monitoring committee / Data safety monitoring board (DSMB/DMC) will be formed to oversee the safety of the trial subjects in the clinical trial by periodically assessing the safety of the trial therapy. The DSMB will consist at least of two physicians who are not involved in the trial and who are external to the sponsor. The study DSMB charter will elaborate the guidelines for the DSMB. The DSMB will meet according to the intervals mentioned in the DSMB Charter.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 25 March 2021 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------|
| Country: Number of subjects enrolled | Austria: 9 |
| Country: Number of subjects enrolled | Germany: 38 |
| Worldwide total number of subjects | 47 |
| EEA total number of subjects | 47 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 10 |
| From 65 to 84 years | 32 |

| | |
|-------------------|---|
| 85 years and over | 5 |
|-------------------|---|

Subject disposition

Recruitment

Recruitment details:

From 25 Mar 2021 through 10 Jun 2022, a total of 49 patients were screened at 11 study sites in Germany and 2 study sites in Austria.

Pre-assignment

Screening details:

47 of 49 screened patients entered the study and received at least one dose of the study drug emicizumab. Overall, 42 patients completed 12 weeks of treatment and 43 started the FU period.

Period 1

| | |
|------------------------------|---------------------------------------|
| Period 1 title | Emicizumab treatment (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|-----------|------------------|
| Arm title | Treatment period |
|-----------|------------------|

Arm description:

Day 1 (6 mg/kg body weight (bw) subcutaneously)

Day 2 (3 mg/kg bw)

Maintenance dose: 1.5 mg/kg bw SC weekly starting week 2 (day 8 to 10) up to week 12

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Emicizumab |
| Investigational medicinal product code | |
| Other name | Hemlibra® |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Emicizumab will be given on day 1 (6 mg/kg body weight (bw) subcutaneously) and day 2 (3 mg/kg bw), followed by maintenance doses of 1.5 mg/kg bw weekly starting week 2 (day 8 to 10) and up to week 12.

Emicizumab treatment will be discontinued in case of achieving spontaneous partial remission of AHA, defined as FVIII activity (chromogenic test with bovine components) increased to >50% of normal.

| Number of subjects in period 1 | Treatment period |
|--------------------------------|------------------|
| Started | 47 |
| Completed | 42 |
| Not completed | 5 |
| partial remission | 1 |
| Consent withdrawn by subject | 1 |
| Physician decision | 2 |
| Adverse event, non-fatal | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|----------------------|
| Reporting group title | Emicizumab treatment |
|-----------------------|----------------------|

Reporting group description: -

| Reporting group values | Emicizumab treatment | Total | |
|--|----------------------|-------|--|
| Number of subjects | 47 | 47 | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 10 | 10 | |
| From 65-84 years | 32 | 32 | |
| 85 years and over | 5 | 5 | |
| Gender categorical Units: Subjects | | | |
| Female | 23 | 23 | |
| Male | 24 | 24 | |

Subject analysis sets

| | |
|----------------------------|-----|
| Subject analysis set title | PPS |
|----------------------------|-----|

| | |
|---------------------------|--------------|
| Subject analysis set type | Per protocol |
|---------------------------|--------------|

Subject analysis set description:

The PPS consisted of all patients who were treated for at least 12 weeks without major protocol deviations.

| Reporting group values | PPS | | |
|--|-----|--|--|
| Number of subjects | 35 | | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |
| Adults (18-64 years) | 8 | | |
| From 65-84 years | 23 | | |
| 85 years and over | 4 | | |

| | | | |
|--------------------|----|--|--|
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 19 | | |
| Male | 16 | | |

End points

End points reporting groups

| | |
|---|------------------|
| Reporting group title | Treatment period |
| Reporting group description: Day 1 (6 mg/kg body weight (bw) subcutaneously) Day 2 (3 mg/kg bw) Maintenance dose: 1.5 mg/kg bw SC weekly starting week 2 (day 8 to 10) up to week 12 | |
| Subject analysis set title | PPS |
| Subject analysis set type | Per protocol |
| Subject analysis set description: The PPS consisted of all patients who were treated for at least 12 weeks without major protocol deviations. | |

Primary: number of clinically significant new bleeds per patient-week

| | |
|---|--|
| End point title | number of clinically significant new bleeds per patient-week |
| End point description: The primary endpoint was the number of clinically significant new bleeds per patient-week after the first dose of emicizumab until Week 12 after starting emicizumab treatment or dropout, whatever occurred first. | |
| End point type | Primary |
| End point timeframe: 12 weeks | |

| End point values | Treatment period | PPS | | |
|-----------------------------|------------------|----------------------|--|--|
| Subject group type | Reporting group | Subject analysis set | | |
| Number of subjects analysed | 47 | 35 | | |
| Units: bleeding rate | | | | |
| number (not applicable) | 22 | 11 | | |

Statistical analyses

| | |
|---|------------------------|
| Statistical analysis title | Full Analysis |
| Comparison groups | Treatment period v PPS |
| Number of subjects included in analysis | 82 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| P-value | < 0.001 |
| Method | Chi-squared |
| Parameter estimate | likelihood-ratio test |
| Confidence interval | |
| level | Other: 2.5 % |
| sides | 1-sided |
| upper limit | 0.061 |
| Variability estimate | Standard deviation |
| Dispersion value | 0.0704 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

12 weeks

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 24.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Overall |
|-----------------------|---------|

Reporting group description: -

| Serious adverse events | Overall | | |
|---|------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 16 / 47 (34.04%) | | |
| number of deaths (all causes) | 1 | | |
| number of deaths resulting from adverse events | 1 | | |
| Injury, poisoning and procedural complications | | | |
| Concussion | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Contusion | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Post procedural hemorrhage | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Transfusion-related circulatory overload | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Traumatic hemorrhage | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Traumatic intracranial hemorrhage | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Shock hemorrhage | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hematoma | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Anal hemorrhage | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal hemorrhage | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intestinal ischemia | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intra-abdominal hemorrhage | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Retroperitoneal hemorrhage | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Cholecystitis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Covid-19 | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infected dermal cyst | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Hyperglycemia | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| Non-serious adverse events | Overall | | |
|---|------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 32 / 47 (68.09%) | | |
| Vascular disorders | | | |
| Hematoma | | | |
| subjects affected / exposed | 3 / 47 (6.38%) | | |
| occurrences (all) | 4 | | |
| Hypertension | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Surgical and medical procedures | | | |
| Catheter placement | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Debridement | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Skin graft | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Wound treatment | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |
| Inflammation | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Vessel puncture site thrombosis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Drug hypersensitivity | | | |

| | | | |
|---|--|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hypogammaglobulinemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 47 (2.13%)</p> <p>1</p> <p>1 / 47 (2.13%)</p> <p>1</p> | | |
| <p>Reproductive system and breast disorders</p> <p>Benign prostatic hyperplasia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 47 (2.13%)</p> <p>1</p> | | |
| <p>Respiratory, thoracic and mediastinal disorders</p> <p>Bronchospasm</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nasal congestion</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 47 (2.13%)</p> <p>1</p> <p>1 / 47 (2.13%)</p> <p>1</p> <p>1 / 47 (2.13%)</p> <p>1</p> | | |
| <p>Psychiatric disorders</p> <p>Depressed mood</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Insomnia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 47 (2.13%)</p> <p>1</p> <p>1 / 47 (2.13%)</p> <p>1</p> | | |
| <p>Investigations</p> <p>Blood bilirubin increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Blood creatinine increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Blood potassium decreased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 47 (2.13%)</p> <p>1</p> <p>1 / 47 (2.13%)</p> <p>1</p> <p>1 / 47 (2.13%)</p> <p>1</p> | | |

| | | | |
|--|---------------------|--|--|
| C-reactive protein increased subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Hemoglobin decreased subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Red blood cell count decreased subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Injury, poisoning and procedural complications | | | |
| Fall subjects affected / exposed occurrences (all) | 2 / 47 (4.26%) 3 | | |
| Contusion subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 2 | | |
| Head injury subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Overdose subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Skin abrasion subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Skin laceration subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Toxicity to various agents subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Congenital, familial and genetic disorders | | | |
| Phimosis subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Cardiac disorders | | | |

| | | | |
|--|---------------------|--|--|
| Atrial fibrillation subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Bradycardia subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Cardiac failure subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 2 / 47 (4.26%) 3 | | |
| Extrapyramidal disorder subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Paresthesia subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Peroneal nerve palsy subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Blood and lymphatic system disorders Anemia subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Lymphadenopathy subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Eye disorders Dry eye subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Eye hemorrhage subjects affected / exposed occurrences (all) | 1 / 47 (2.13%) 1 | | |
| Gastrointestinal disorders | | | |

| | | | |
|--|----------------|--|--|
| Diarrhea | | | |
| subjects affected / exposed | 3 / 47 (6.38%) | | |
| occurrences (all) | 3 | | |
| Constipation | | | |
| subjects affected / exposed | 2 / 47 (4.26%) | | |
| occurrences (all) | 2 | | |
| Diverticulum | | | |
| subjects affected / exposed | 2 / 47 (4.26%) | | |
| occurrences (all) | 2 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Barrett's esophagus | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Chronic gastritis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Gastritis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Gastroesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Ileus | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Proctitis ulcerative | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|----------------|--|--|
| Rash | | | |
| subjects affected / exposed | 2 / 47 (4.26%) | | |
| occurrences (all) | 2 | | |
| Dermal cyst | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Erythema | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Skin hemorrhage | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Urticaria | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 2 / 47 (4.26%) | | |
| occurrences (all) | 2 | | |
| Bladder disorder | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Renal cyst | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Ureterolithiasis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Urinary incontinence | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Back pain | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Muscle hemorrhage | | | |

| | | | |
|---------------------------------|----------------|--|--|
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Muscle spasms | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Infections and infestations | | | |
| COVID-19 | | | |
| subjects affected / exposed | 2 / 47 (4.26%) | | |
| occurrences (all) | 2 | | |
| Bacteriuria | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Device related infection | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Laryngitis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Urosepsis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |

| | | | |
|------------------------------------|----------------|--|--|
| Metabolism and nutrition disorders | | | |
| Hyperkalemia | | | |
| subjects affected / exposed | 2 / 47 (4.26%) | | |
| occurrences (all) | 2 | | |
| Fluid overload | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Hyperglycemia | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Hyperuricemia | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Hypocalcemia | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Hyponatremia | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Hypokalemia | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Lactic acidosis | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |
| Vitamin K deficiency | | | |
| subjects affected / exposed | 1 / 47 (2.13%) | | |
| occurrences (all) | 1 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|--|
| 15 March 2022 | Version 3.0 dated 01 Mar 2022 including new safety information from updated Investigator’s Brochure and adaptation of study procedures |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported